BSE filing, NSE: JENBURPH. Summary written from the filing by ALFA Finder's alert engine.
Jenburkt Pharmaceuticals Ltd: key numbers
- Share price
- ₹892.90
- Market cap
- ₹394.1 Cr
- Revenue (annual)
- ₹168.7 Cr
- Net profit (annual)
- ₹34.74 Cr
- P/E (TTM)
- 12.0×Sector 46.1×
- Promoter holding
- 46.62%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jenburkt Pharmaceuticals Ltd
All →Jenburkt Pharmaceuticals Capital Structure Change
Counter Cyclical Investments Private Limited acquired 326 shares of Jenburkt Pharmaceuticals Ltd in the open market, increasing its total shareholding from 4.99% to 5.01%.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals submitted a certificate under SEBI Regulation 74(5) regarding share dematerialization for the quarter ended September 30, 2026.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.
Jenburkt Pharmaceuticals Management Change
Mr. Vinay Bhatt, Senior Vice President- International Business, has resigned from Jenburkt Pharmaceuticals Limited effective September 18, 2026, due to personal reasons.
Jenburkt Pharmaceuticals Annual General Meeting
Jenburkt Pharmaceuticals held its 41st Annual General Meeting on 4th September, 2026, to discuss financial statements, dividend declaration, and director appointments.
Jenburkt Pharmaceuticals Management Change
Jenburkt Pharmaceuticals elevated Shri Prem Ashish Bhuta to Associate Vice President – Strategic Initiatives. He is now classified as Senior Management Personnel effective September 4, 2026.
Other board meeting date announcements
All →Tapi Fruit Processing Board Meeting Date
Tapi Fruit Processing will hold a board meeting on November 3, 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes from October 1 to November 5, 2026.
Parag Milk Foods Board Meeting Date
Parag Milk Foods has notified BSE of a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Trading window closure runs from 1 October to 5 November 2026.
Vedant Fashions Board Meeting Date
Vedant Fashions will hold a board meeting on 5 November 2026 to consider unaudited results for the quarter and half-year ended September 2026. The meeting is a prior intimation, so no results are approved yet.
Dangee Dums Board Meeting Date
Dangee Dums will hold a board meeting on 2 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. Trading window closure runs until 4 November 2026.
Relic Technologies Board Meeting Date
Relic Technologies intimated a board meeting on 2 Nov 2026 to consider unaudited standalone and consolidated Q2 results for the period ended 30 Sep 2026. The trading window closes from 1 Oct 2026 until 48 hours after the results are disseminated.
EPL Board Meeting Date
EPL will hold a board meeting on November 4, 2026 to consider September quarter results. Trading window re-opens 48 hours after results are declared.